PITPNM2

Across TCGA pan-cancer cohorts, PITPNM2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PITPNM2 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PITPNM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PITPNM2 expression acts as an unfavorable survival marker.

SCLC, BLCA, and KIRP are the cancer types where PITPNM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	24	view →
BLCA	OS	Median	All	0.149	0.687	.005	18	view →
KIRP	DFS	Median	All	0.181	0.768	.004	9	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
STAD	OS	Median	II,III,IV	0.153	0.566	.013	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
LUAD	OS	Median	All	0.277	0.787	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PITPNM2–SCLC (OS)

Open the SCLC breakdown →